Global (NYSE:SPIR) shares, bringing it down from $24.00 to $11.50, while maintaining a Buy rating on the stock. Currently trading at $10.12, the stock has experienced significant volatility, with ...

Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...

Canaccord Genuity has downgraded Pliant (PLRX) to hold following news that the company has paused a clinical trial for its ...

The surprise retirement of Dunelm's boss shouldn't put off investors from the homeware retailer's strong growth prospects, ...

Aurora Innovation, Inc. (NASDAQ: AUR) today announced David Maday, Chief Financial Officer, will participate in a virtual ...

In a report released yesterday, Alexander Bedwany from Canaccord Genuity reiterated a Buy rating on Kodal Minerals (KOD – Research Report), ...

Uncertainty around North American trade has hindered capital-markets activity and stalled investments in Canada, according to ...

A big dividend yield for a few years doesn't mean much if it can't be sustained. While Canaccord Genuity Group is not profitable, it is paying out less than 75% of its free cash flow, which means ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Canaccord Genuity Group in a note issued to investors on Monday, MarketBeat reports.

Canaccord Genuity analyst Alexander Bedwany reiterated a Sell rating on South32 Ltd. (S32 – Research Report) yesterday and set a price target ...

Analysts at Canaccord Genuity slightly raised their target price on Celtic from 202.0p to 208.0p on Tuesday, stating the firm ...